Altitude and COPD prevalence: Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study

the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors. Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD. Results: Among 30,874 participants aged 56.1±11.3years from 44 sites worldwide, 55.8% were women, 49.6% never-smokers, and 12.9% (3978 subjects) were residing above 1500m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p<0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude. Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.

Original languageEnglish (US)
Article number162
JournalRespiratory Research
Volume18
Issue number1
DOIs
StatePublished - Aug 23 2017

Fingerprint

Chronic Obstructive Pulmonary Disease
Cisplatin
Bronchodilator Agents
Oceans and Seas
Multivariate Analysis

Keywords

  • COPD
  • Epidemiology
  • Geographical altitude
  • Risk factors
  • Underdiagnosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group (2017). Altitude and COPD prevalence: Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respiratory Research, 18(1), [162]. https://doi.org/10.1186/s12931-017-0643-5

Altitude and COPD prevalence : Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. / the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group.

In: Respiratory Research, Vol. 18, No. 1, 162, 23.08.2017.

Research output: Contribution to journalArticle

the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group 2017, 'Altitude and COPD prevalence: Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study', Respiratory Research, vol. 18, no. 1, 162. https://doi.org/10.1186/s12931-017-0643-5
the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group. Altitude and COPD prevalence: Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. Respiratory Research. 2017 Aug 23;18(1). 162. https://doi.org/10.1186/s12931-017-0643-5
the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group. / Altitude and COPD prevalence : Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study. In: Respiratory Research. 2017 ; Vol. 18, No. 1.
@article{90619fbb6a1c4c8d8fc1c8835508c339,
title = "Altitude and COPD prevalence: Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study",
abstract = "Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors. Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD. Results: Among 30,874 participants aged 56.1±11.3years from 44 sites worldwide, 55.8{\%} were women, 49.6{\%} never-smokers, and 12.9{\%} (3978 subjects) were residing above 1500m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5{\%} compared to 9.9{\%}, respectively (p<0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude. Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.",
keywords = "COPD, Epidemiology, Geographical altitude, Risk factors, Underdiagnosis",
author = "{the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group} and Andreas Horner and Soriano, {Joan B.} and Puhan, {Milo A.} and Michael Studnicka and Bernhard Kaiser and Vanfleteren, {Lowie E.G.W.} and Louisa Gnatiuc and Peter Burney and Marc Miravitlles and Francisco Garc{\'i}a-Rio and Julio Ancochea and Menezes, {Ana M.} and Rogelio Perez-Padilla and {Montes de Oca}, Maria and Torres-Duque, {Carlos A.} and Andres Caballero and Mauricio Gonz{\'a}lez-Garc{\'i}a and Buist, {A (Sonia)} and Maria Flamm and Bernd Lamprecht",
year = "2017",
month = "8",
day = "23",
doi = "10.1186/s12931-017-0643-5",
language = "English (US)",
volume = "18",
journal = "Respiratory Research",
issn = "1465-9921",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Altitude and COPD prevalence

T2 - Analysis of the PREPOCOL-PLATINO-BOLD-EPI-SCAN study

AU - the BOLD Collaborative Research Group, the EPI-SCAN Team, the PLATINO Team and the PREPOCOL Study Group

AU - Horner, Andreas

AU - Soriano, Joan B.

AU - Puhan, Milo A.

AU - Studnicka, Michael

AU - Kaiser, Bernhard

AU - Vanfleteren, Lowie E.G.W.

AU - Gnatiuc, Louisa

AU - Burney, Peter

AU - Miravitlles, Marc

AU - García-Rio, Francisco

AU - Ancochea, Julio

AU - Menezes, Ana M.

AU - Perez-Padilla, Rogelio

AU - Montes de Oca, Maria

AU - Torres-Duque, Carlos A.

AU - Caballero, Andres

AU - González-García, Mauricio

AU - Buist, A (Sonia)

AU - Flamm, Maria

AU - Lamprecht, Bernd

PY - 2017/8/23

Y1 - 2017/8/23

N2 - Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors. Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD. Results: Among 30,874 participants aged 56.1±11.3years from 44 sites worldwide, 55.8% were women, 49.6% never-smokers, and 12.9% (3978 subjects) were residing above 1500m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p<0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude. Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.

AB - Background: COPD prevalence is highly variable and geographical altitude has been linked to it, yet with conflicting results. We aimed to investigate this association, considering well known risk factors. Methods: A pooled analysis of individual data from the PREPOCOL-PLATINO-BOLD-EPI-SCAN studies was used to disentangle the population effect of geographical altitude on COPD prevalence. Post-bronchodilator FEV1/FVC below the lower limit of normal defined airflow limitation consistent with COPD. High altitude was defined as >1500m above sea level. Undiagnosed COPD was considered when participants had airflow limitation but did not report a prior diagnosis of COPD. Results: Among 30,874 participants aged 56.1±11.3years from 44 sites worldwide, 55.8% were women, 49.6% never-smokers, and 12.9% (3978 subjects) were residing above 1500m. COPD prevalence was significantly lower in participants living at high altitude with a prevalence of 8.5% compared to 9.9%, respectively (p<0.005). However, known risk factors were significantly less frequent at high altitude. Hence, in the adjusted multivariate analysis, altitude itself had no significant influence on COPD prevalence. Living at high altitude, however, was associated with a significantly increased risk of undiagnosed COPD. Furthermore, subjects with airflow limitation living at high altitude reported significantly less respiratory symptoms compared to subjects residing at lower altitude. Conclusion: Living at high altitude is not associated with a difference in COPD prevalence after accounting for individual risk factors. However, high altitude itself was associated with an increased risk of undiagnosed COPD.

KW - COPD

KW - Epidemiology

KW - Geographical altitude

KW - Risk factors

KW - Underdiagnosis

UR - http://www.scopus.com/inward/record.url?scp=85028326343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028326343&partnerID=8YFLogxK

U2 - 10.1186/s12931-017-0643-5

DO - 10.1186/s12931-017-0643-5

M3 - Article

C2 - 28835234

AN - SCOPUS:85028326343

VL - 18

JO - Respiratory Research

JF - Respiratory Research

SN - 1465-9921

IS - 1

M1 - 162

ER -